Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

Paradoxical psoriasis is a rare but increasingly recognized adverse effect of anti-TNF-α therapy, characterized by the onset or exacerbation of psoriatic lesions in patients treated for other immune-mediated conditions. We report the case of a 47-year-old woman with chronic plaque psoriasis who dev...

Full description

Bibliographic Details
Published in:	Dermatology Reports
Main Authors:	Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo
Format:	Article
Language:	English
Published:	PAGEPress Publications 2025-05-01
Subjects:	Paradoxical psoriasis generalized pustular psoriasis adalimumab biosimilar brodalumab
Online Access:	https://www.pagepress.org/journals/dr/article/view/10414

Similar Items

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: a Narrative Review
by: Maria Vittoria Cannizzaro, et al.
Published: (2023-07-01)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
by: Reem Kashlan, MPH, et al.
Published: (2021-04-01)

Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022-12-01)

Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab
by: Daniela Anghel, et al.
Published: (2023-12-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

Brodalumab
by: Murat Borlu
Published: (2022-04-01)

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Brodalumab in the Treatment of Various Forms of Psoriasis: A Narrative Review
by: Aditya K. Bubna, et al.
Published: (2025-01-01)

Adalimumab induced psoriasis in a Crohn’s disease patient: a case report
by: Dhaifallah Alrakawi Alenizi
Published: (2024-06-01)

Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning
by: Babaei N, et al.
Published: (2025-07-01)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
by: Kristian Reich, et al.
Published: (2022-03-01)

Analysis and mining of brodalumab adverse events based on FAERS database
by: Yue Wan, et al.
Published: (2025-05-01)

Generalized pustular psoriasis with breast cancer successfully treated with granulocyte and monocyte adsorptive aphaeresis and brodalumab
by: Miho Takahashi, et al.
Published: (2025-03-01)

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
by: David M. Pariser, et al.
Published: (2025-03-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2023-07-01)

Pustular Psoriasis: From Pathophysiology to Treatment
by: Giovanni Genovese, et al.
Published: (2021-11-01)

Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
by: Liz S. Gea, et al.
Published: (2024-10-01)

First experiences in real clinical practice treating a patient with generalised pustular psoriasis with Spesolimab
by: Aurora Fernández‐Galván, et al.
Published: (2023-06-01)

Acute Generalized Pustular Psoriasis Developed Resistance to Adalimumab Was Successfully Treated with Narrowband Ultraviolet B and Acitretin: A Case Report
by: Yang X, et al.
Published: (2022-11-01)

Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)
by: Paolo Dapavo, et al.
Published: (2023-12-01)

Pustular psoriasis of pregnancy: current perspectives
by: Trivedi MK, et al.
Published: (2018-02-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Efficacy and Tolerability of Brodalumab in 42 Adult Patients With Moderate to Severe Psoriasis: First French Real‐Life Case Series on Hard‐to‐Treat Areas
by: Marc Perrussel, et al.
Published: (2025-09-01)

Pustular Psoriasis: The Dawn of a New Era
by: Hervez Bachelez
Published: (2020-01-01)

Characteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis Group
by: Marta Kołt-Kamińska, et al.
Published: (2024-11-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
by: Alan Menter
Published: (2023-10-01)

Phenotypic differences in clinical manifestations of generalized pustular psoriasis and severe plaque psoriasis in tropical Taiwan
by: Yin-Cheng Chao, et al.
Published: (2024-09-01)

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study
by: Francesco Bellinato, et al.
Published: (2023-03-01)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
by: Cacciapuoti S, et al.
Published: (2023-09-01)

Adrenal Insufficiency Secondary to Abrupt Dose Reduction of Topical Corticosteroid Therapy after Starting Brodalumab for Psoriasis: A Case Report
by: Mariko Yamane, et al.
Published: (2022-03-01)

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
by: Ran Jin, et al.
Published: (2025-03-01)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Natalizumab-Induced Pustular Psoriasis of Palms and Soles
by: Bengisu Ozarslan, et al.
Published: (2022-05-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
by: Lisa Schaeffer, et al.
Published: (2024-12-01)

Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials
by: Vibeke Strand
Published: (2025-06-01)

Clinical Characteristics of Patients with Pustular Psoriasis: A Single-Center Retrospective Observational Study
by: Paolo Gisondi, et al.
Published: (2022-07-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)